首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1461375

糖尿病视网膜病变市场：现况分析与预测（2023-2030）

Diabetic Retinopathy Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年03月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 152 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

由于老年人口的增加，糖尿病视网膜病变市场预计在预测期内将以 9.1% 的复合年增长率强劲增长。例如，根据美国人口普查局的数据，到2050年，全球65岁及以上的人口将达到16亿，是2018年人口的两倍多。同样，世界卫生组织 (WHO) 估计，到 2050 年，60 岁及以上的人口数量将从 2017 年的 9.62 亿增加近两倍，达到 21 亿。这些统计数据表明，世界各地的老年人口正在显着增加。传播对这种疾病的认识非常重要，以便患者能够及早诊断并寻求适当的医疗照护。导致糖尿病视网膜病变发病和进展的因素包括长期糖尿病、血糖控制不佳、高血压、胆固醇水平升高、吸烟、家族史和遗传倾向。此外，不良的生活习惯也促进了糖尿病视网膜病变市场的成长。

依类型分为增殖性糖尿病视网膜病变和非增殖性糖尿病视网膜病变。非增殖性糖尿病视网膜病变领域由于近年来盛行率较高，到2022年将占大部分市场占有率。在非增殖性糖尿病视网膜病变中，长期暴露于高血糖会损害视网膜中的小血管。然而，随着病情的进展，症状包括视力模糊、阅读困难和辨别颜色困难。糖尿病患者数量的增加导致了这种疾病在全球范围内的传播。因此，在2022年的预测期内，非增殖性糖尿病视网膜病变类别占据了市场的大部分占有率。

根据应用，市场分为诊断和治疗。预计治疗领域将在预测期内显着成长。治疗领域是由不断进步的技术所推动的。糖尿病视网膜病变市场治疗领域的成长是由疾病盛行率的增加、医疗保健服务的改善以及对早期介入和联合治疗方法的日益重视所推动的。对研发的持续投资，以及改善患者获得有效治疗的努力，预计将在预测期内维持治疗产业的成长轨迹。因此，预计在预测期内，治疗领域将在市场上占据显着地位。

为了更瞭解市场，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）和亚太地区（中国、日本、印度、亚太地区其他地区）和世界其他国家是根据其在世界上的存在进行分析的。2022年糖尿病视网膜病变市场由北美主导。有几个因素正在推动该地区的市场发展，包括糖尿病视网膜病变病例数量的增加、创新的仿製药供应、人们对糖尿病视网膜病变的认识不断提高、企业合作伙伴关係以及该地区老年人口的增加。例如，40岁以上有894万人患有糖尿病视网膜病变，40岁以上有171万人患有威胁视力的糖尿病视网膜病变。依地区划分，2022年糖尿病视网膜病变市场将由北美主导。

Diabetic retinopathy is a complication of diabetes that affects the eyes. It occurs when high blood sugar levels damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. As the global population ages, the incidence of diabetic retinopathy is expected to rise, thus fueling the demand for treatment options. The rising awareness about diabetic retinopathy also plays a significant role in driving growth in the diabetic retinopathy market. Increased awareness efforts by government health agencies, non-profit organizations, and healthcare providers have raised public consciousness about the importance of regular eye examinations for individuals with diabetes. Additionally, technological advancements in drug development have increased in recent years further driving the market growth.

The Diabetic Retinopathy Market is expected to grow at a strong CAGR of 9.1% during the forecast period owing to the rising geriatric population. For instance, according to the U.S. Census Bureau, the global population aged 65 and older will reach 1.6 billion by 2050, more than double the population in 2018. Similarly, the World Health Organization (WHO) estimates that the number of people aged 60 and above will nearly triple by 2050, from 962 million in 2017 to 2.1 billion. These statistics indicate a significant increase in the geriatric population worldwide. Spreading awareness about the disease is very crucial to help patients diagnose the disease in early stages and search for appropriate medical treatment. Driving factors contributing to the development and progression of diabetic retinopathy are longer duration of diabetes, poor blood sugar control, high blood pressure, elevated cholesterol levels, smoking, family history, and genetic predisposition. The surge in poor lifestyles also contributes to the growth of the diabetic retinopathy market.

Based on types, the market is bifurcated into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy segment held the majority share of the market in 2022 because of the higher prevalence of the disease in recent years. In non-proliferative diabetic retinopathy, the small blood vessels in the retina are damaged due to prolonged exposure to high levels of blood sugar. However, if the condition progresses, patients experience blurred vision, difficulty reading, and difficulty in differentiating colors. Growing cases of diabetes are leading to the growth of the disease worldwide. Hence, the non-proliferative diabetic retinopathy category held the majority share of the market in the year 2022 during the forecast period.

Based on application, the market is bifurcated into diagnosis and treatment. The treatment segment is expected to grow at a significant rate in the forecast period. The driving factor for the treatment segment is the growing technological advancements. The growth of the treatment segment in the diabetic retinopathy market is driven by increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Continued investment in research and development, along with efforts to improve patient access to effective treatments, will likely sustain the growth trajectory of the treatment segment in the forecast period. Thus, the treatment segment is expected to gain prominence in the market in the forecast period.

For a better understanding, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market of diabetic retinopathy in 2022. Several factors such as the growing cases of diabetic retinopathy, availability of innovative generics, growing awareness of diabetic retinopathy, company collaborations, and the rising geriatric population in the region are driving the market in the region. For instance, there were 8.94 million people aged >=40 years with diabetic retinopathy and 1.71 million people aged >=40 years with vision-threatening diabetic retinopathy. North America dominated the diabetic retinopathy market among regions in the year 2022.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd; Novartis AG; Regeneron Pharmaceuticals Inc.; Bayer AG; Coherus BioSciences, Inc.; KODIAK SCIENCES INC.; HANLIM PHARM.CO.LTD.; Sanofi; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.

1.MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Diabetic Retinopathy Market
2.2.Research Methodology of the Diabetic Retinopathy Market
2.3.Respondent Profile

3.MARKET SYNOPSIS

4.EXECUTIVE SUMMARY

5.IMPACT OF COVID-19 ON THE DIABETIC RETINOPATHY MARKET

6.DIABETIC RETINOPATHY MARKET REVENUE (USD BN), 2020-2030F

7.MARKET INSIGHTS BY TYPE

7.1.Proliferative Diabetic Retinopathy
7.2.Non-proliferative Diabetic Retinopathy

8.MARKET INSIGHTS BY APPLICATION

8.1.Diagnosis
- 8.1.1.Visual Acuity Testing
- 8.1.2.Fluorescein Angiography
- 8.1.3.Optical Coherence Tomography (OCT)
- 8.1.4.Others
8.2.Treatment
- 8.2.1.Anti-VEGF Drugs
- 8.2.2.Laser Surgeries
- 8.2.3.Others

9.MARKET INSIGHTS BY REGION

9.1.North America
- 9.1.1.U.S.
- 9.1.2.Canada
- 9.1.3.Rest of North America
9.2.Europe
- 9.2.1.Germany
- 9.2.2.U.K.
- 9.2.3.France
- 9.2.4.Italy
- 9.2.5.Spain
- 9.2.6.Rest of Europe
9.3.Asia-Pacific
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.India
- 9.3.4.Rest of Asia-Pacific
9.4.Rest of World

10.DIABETIC RETINOPATHY MARKET DYNAMICS

10.1.Market Drivers
10.2.Market Challenges

11.DIABETIC RETINOPATHY MARKET OPPORTUNITIES

12.DIABETIC RETINOPATHY MARKET TRENDS

13.DEMAND AND SUPPLY-SIDE ANALYSIS

13.1.Demand Side Analysis
13.2.Supply Side Analysis

14.VALUE CHAIN ANALYSIS

15.COMPETITIVE SCENARIO

15.1.Competitive Landscape
- 15.1.1.Porters Fiver Forces Analysis

16.COMPANY PROFILED

16.1.F. Hoffmann-La Roche Ltd
16.2.Novartis AG
16.3.Regeneron Pharmaceuticals Inc.
16.4.Bayer AG
16.5.Coherus BioSciences, Inc.
16.6.KODIAK SCIENCES INC.
16.7.HANLIM PHARM.CO.LTD.
16.8.Sanofi
16.9.Intas Pharmaceuticals Ltd.
16.10.Sun Pharmaceutical Industries Ltd.

17.DISCLAIMER

02-2729-4219

+886-2-2729-4219

License/价格

糖尿病视网膜病变市场：现况分析与预测（2023-2030）

Diabetic Retinopathy Market: Current Analysis and Forecast (2023-2030)

目录

第一章市场介绍

第二章研究方法或前提条件

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对糖尿病视网膜病变市场的影响

第六章 2020-2030 年糖尿病视网膜病变市场收入

第七章依类型划分的市场分析

第八章应用市场分析

第九章区域市场分析

第10章糖尿病视网膜病变市场动态

第十一章糖尿病视网膜病变市场机会

第十二章糖尿病视网膜病变市场趋势

第十三章供需分析

第十四章价值链分析

第15章竞争场景

第十六章公司简介

第十七章免责声明